Abbott Laboratories is undervalued with strong growth in diabetes care and weight-loss markets. Discover why ABT stock is a ...

Abbott Laboratories ABT has witnessed strong momentum in the past year. Shares of the company have risen 12.7% compared with the 9% growth of the industry during the same time frame. The S&P 500 ...

Abbott Laboratories' medical device business is executing well, with double-digit growth in structural heart and diabetes.

If you buy and hold a stock for many years, you'd hope to be making a profit. Better yet, you'd like to see the ...

The company is first rolling out the use of the Volt system among European Union doctors who have already gained experience ...

In a report released today, Joanne Wuensch from Citi maintained a Buy rating on Abbott Laboratories (ABT – Research Report). The company’s ...

Johnson & Johnson and Boston Scientific have also recently made moves to sell their own coronary intravascular lithotripsy ...

Abbott Laboratories (NYSE: ABT) stock was in fine health on the second-to-last trading day of the week, thanks to news from Europe. The CE mark is an affirmation by a product's manufacturer that it ...

Abbott (ABT) announced it has received CE Mark in Europe for the Volt PFA System to treat patients battling atrial fibrillation. With the ...

Abbott is joining the worldwide race to make pulsed field ablation the standard procedure for atrial fibrillation with an ...